ICCC ImmuCell Corp.
ImmuCell Corp. (ICCC) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Where they traded
Last open-market purchase: June 18, 2026 , by te Boekhorst Paul Francis Olivier .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| te Boekhorst Paul Francis Olivier | President and CEO | Buy | 8,000 | $9.49 | $76.0K | 17,785 | |
| te Boekhorst Paul Francis Olivier | President and CEO | Buy | 2,432 | $5.50 | $13.4K | 9,738 | |
| te Boekhorst Paul Francis Olivier 3 fills | President and CEO | Buy | 9,675 | $5.03 | $48.7K | 9,785 | |
| te Boekhorst Paul Francis Olivier | President and CEO | Buy | 3,708 | $4.87 | $18.1K | 3,708 | |
| Tomsche David Scott 2 fills | Director | Buy | 3,266 | $4.76 | $15.6K | 52,720 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.